Data from NSCLC patients demonstrated that KRAS mutation is very low in NSCLC but high in pancreatic cancer, and that it has a significantly lower benefit from EGFR tyrosine kinase inhibitor. This evidence concerns the gene EGFR and pancreatic neoplasm.